Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLOSE IT extension study of Fiasp in fully automated insulin delivery for type 1 diabetes
ACTRN12622001401741Phase 2Completed
- Sponsor
- Baker Heart and Diabetes Institute
- Start
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of human insulin in diabetes mellitus type 1 (T1D), sponsored by Baker Heart and Diabetes Institute. Primary endpoint: Time in range 3.9-10.0 mmol/L. Started Oct 2023; status: completed.
02
Drugs
human insulin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ACTRN12622001401741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001401741.